Dr. Sophie Kirschner, Associate Director, Translational Medicine, Early Oncology at AstraZeneca will present data using biomodal’s 6-base multiomics sequencing solution, duet evoC.
Distinguishing 5mC and 5hmC, enabled through duet evoC and the 6-base genome, delivered an AUC of 0.95 for stage I colorectal cancer from liquid biopsy, improving the earlier detection of stage I colorectal cancer from cfDNA samples!
biomodal announced it has filed a lawsuit against Watchmaker Genomics (“Watchmaker”) in the US District Court for the District of Colorado.
Explore the importance of epigenetics and how it shapes health, disease, and precision medicine through gene regulation, and DNA methylation.
This study demonstrates the value of moving beyond legacy epigenetic sequencing technologies that provide a modC readout.
Using modality XPLR, we reveal variation in 5mC and 5hmC levels across tissues, with a pronounced increase in 5hmC in cerebellum and concomitant decrease in 5mC.
This poster demonstrates compatibility of duet evoC with formalin-damaged DNA including clinical FFPE samples.
Patterns of 5hmC and 5hmC provide insight into tissue-specific gene expression with the ability to better distinguish high and low expressed genes than 5mC or 5modC data.
biomodal’s Certified Service Provider (CSP) program partners with organisations around the globe to meet the increasing demand for its novel duet multiomics solutions.
Functional genomics is a crucial part of research and development within healthcare because it closes the gap between genetic information and biological function